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Summary 
The incidence of type I diabetes increases dramatically each year. This disease practically 
always causes severe complications in every system. The main complications are cardiovascular, 
neural and kidney pathologies. Complications occur even in case of aggressive treatment of 
hyperglycemia and proper diet. This leads to the conclusion that other factors are involved in the 
progression of the disease. Recent data indicates that C-peptide has an important role in different 
processes in human organism.  In this article is presented a review of C-peptide studies regarding 
its beneficial role in type I diabetes. 
 
Rezumat 
Utilizarea posibila a peptidei C în diabetul zaharat de tip I 
Incidenţa diabetului zaharat de tip I creşte dramatic în fiecare an. Ca regulă, această 
maladie determină complicaţii severe la nivelul tuturor sistemelor. Principalele complicaţii sunt 
patologiile cardiovasculare, neuronale şi renale. Complicaţiile apar chiar şi în cazul unui 
tratament intens al hiperglicemiei şi al unei diete adecvate. Acest fapt permite de a presupune că 
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şi alţi factori sunt implicaţi în progresia bolii. Recent a fost presupus că peptida C ar avea un rol 
important în diferite procese din organism. În acest articol este prezentată o analiză a studiilor 
referitoare la rolul benefic al peptidei C în diabetul zaharat de tip I. 
 
Introduction 
The incidence of type I diabetes (T1D) rises 3-5% each year. This disease is linked to 
severe complications which to some extend are managed with insulin injection and correct diet. 
Still T1D is a disease with high rate of morbidity and mortality due to its complications. 
Practically every system is affected by the disease among which are nervous, cardiovascular, 
excretory etc. The highest mortality rate in diabetic patients is associated with end stage of 
kidney disease. Other risk factors include obesity, insulin resistance and vascular problems. 
One of the major problems of diabetes mellitus is micro and macroangiopathy. Clinical 
studies show that aggressive treatment of hyperglycemia is helpful but doesn’t completely 
reduce the risk for vascular diseases. This leads to the conclusion that hyperglycemia or the 
absence of insulin is not the main problem in case of type I diabetes. Recent data indicates that 
C-peptide can have potential beneficial effects in T1D. It is important to understand that people 
with T1D unlike type II diabetes have not only reduced insulin synthesis but also C-peptide 
which is a part of proinsulin. Possibly C-peptide is one of the substances that should be 
administrated at the same level as insulin in case of T1D. For a long period of time C-peptide 
was considered biologically not relevant. Radioactive labeled C-peptide binds with the cells 
surface receptor, which means that our organism has a receptor complex for it and thus it has 
some role in it [1, 7, 8, 10]. 
 
C-peptide structure 
C-peptide is a small 31-amino acid peptide. It is synthesized with insulin but later on 
cleaved from it. Proinsulin consists of 3 peptide chains: A, B and C. C-peptide is stored in 
secretory granules along with insulin and is secreted equimolar with it into the blood stream. 
Unlike insulin its half-live is 30 minutes. The molecular structure of C-peptide varies, but still it 
has several conservative regions found in different species. For example: N terminal acidic 
region, glycine-rich central segment, and C-terminal pentapeptide [10]. 
In mammals 8 residues in C-peptide are especially conservative. These are 1 (Glu), 3 
(Glu), 6 (Gln), 11 (Glu), 12 (Leu), 26 (Leu), 27 (Glu) and 31 (Gln). C-peptide is a highly acidic 
peptide. It has 5 acidic residues in humans, with no counterbalance from the basic residues. The 
current data indicates that it has a G-protein coupled receptor [11]. 
 
Effects on cardiovascular system 
With time almost all T1D patients develop angiopathy. One of the major beneficial roles 
of C-peptide is its effect on cardiovascular system. 
C-peptide increases intracellular Ca
2+
, which can affect nitric oxide (NO) production 
through nitric oxide synthase. This causes NO-dependent vasodilatation, which is important as 
vaso and cardioprotective effect [8]. 
C-peptide decreases smooth muscle proliferation through inhibition of platelet-derived 
growth factor receptor (PDGFr) and increases phosporylation of mitogen-activating protein 
kinase (MAPK). This effect decreases the risk for atherosclerosis [8]. 
Bo-Lennart Johansson et al., 2004 showed a significant improvement of left ventricular 
function in diabetic patients. Another problem in diabetic patients is red cell deformities. This 
results in high risk of thrombosis and decreased oxygen transport to the peripheral tissues. The 




-ATPase on erythrocyte surface [6].  
C-peptide decreases the expression of endothelial cell adhesion molecules. Can reduce 
leukocyte adhesion to endothelium preventing inflammation. In some experimental models 




Effects on central and peripheral nervous tissue 
Neuropathy is another major problem in T1D which affects most of patients to some 
extent. It affects both central and peripheral nervous system. 
In patient with neuropathies due to diabetes administration of C-peptide resulted in 80% 
correction of system conduction velocity with major improvement of sensory and motor 
functions as well as vibration sensation. But cold and warm sensation remains at the same level 
[3].  
C-peptide prevents neuronal apoptosis in T1D. Promotes cell growth of neuroblastoma 
cell line in vitro. It protects neurons against swelling and degeneration [8]. 
Several cognitive impairments were associated with hippocampal apoptotic neuronal loss 
in diabetic patients. Diabetic mice with c-peptide administration showed significant spatial 
learning and memory improvements. C-peptide prevents oxidative stress and inhibits apoptosis, 
increases NF-κB production. NF-κB plays a role in neuron plasticity, learning, and memory [9]. 
 
Effects on kidney function 
End stage kidney disease is considered to be the main cause of mortality among T1D 
patients. 
C-peptide prevents tumor necrotic factor-mediated (TNF) apoptosis in proximal tubular 
cells, thus decreasing the progression of diabetes-related kidney disease [8]. 
One of the major problems in diabetic nephropathies is the epithelial-mesenchymal 
transformation due to the effect of transforming grow factor-b1 (TGF-b1). C-peptide prevents 





-ATPase increasing its activity. This is useful to increase kidney 
filtration and reassertion. Mouse models also show reducing glomerular hyperfiltration, 
hypertrophy and proteinuria. This can prove to be useful in case of first signs of kidney disease 
until transplantation can be performed. 
 
Effects on lungs and possible use in critical care 
C-peptide administration can be beneficial in diabetic as well as non-diabetic patients 
after trauma during systemic inflammation response and other critical conditions. It reduces the 
level of IL-1, IL-6, macrophage inflammatory protein-1a and cytokine-induced neutrophil 
chemoattractant-1. This decreases neutrophil infiltration and ameliorates inflammatory 
processes. Additionally C-peptide improves blood flow in lung tissue [2]. 
Due to its effect on neutrophils C-peptide can be a useful treatment for several syndromes 
such as: acute respiratory distress syndrome, acute lung injury and several other diseases that are 
encountered in the field of emergency medicine. 
 
Metabolic effects 
Several authors describe insulinomimetic effects in some tissues. C-peptide activates 
insulin receptor tyrosine kinase, insulin receptor substrate, phosphoinositol 3-kinase and MAPK 
phosphorylation, increases amino acid uptake. At the same time other researchers indicate 
glucose transport not using any insulin-like mechanism but with a separate molecular method 
[11]. 
C-peptide can disaggregate insulin, this increases its bioavailability because of 
monomerization [6].  
It is important to mention that the use of C-peptide in non-diabetic patients still doesn’t 
show any significant improvement. It is explained by the fact that increased C-peptide 





C-peptide has several important functions in our organism. Presumably this can be one of 
the possible reasons of multiple diabetes-associated complications even in case of aggressive 
glucose control and diet. 
C-peptide affects multiple cells and systems in the body which can be summarized in 
Table 1. Using molecular methods several authors indicate that C-peptide binds in great amounts 
to renal convoluted tubular cells, skin fibroblasts, and saphenous vein endothelial cells, 




-ATPase increasing its activity. The main cells 
affected by this mechanism are renal and nervous tissues [11]. 
It is important to note that some authors indicate C-peptide self-association. This can 
cause aggregation of peptides which can lead to amyloid-like formations [6]. Thus injection of 
C-peptide should be carefully measured. 
Table 1 
C-peptide’s physiological and chemical beneficial effects in different tissues 
Tissue Cells Effect Result 
























Improvements of endoneural 
blood flow, 
prevents axonal swelling and 
decreases oxidative stress 
Decreases the risk for 
neuropathies, improves 
sensory and motor neuron 
function 













Kidney tissue Kidney glomeruli Reducing glomerular 
hyperfiltration, hypertrophy 
and proteinuria 
Prevents renal damage 
Proximal tubular cells Prevents apoptosis Prevents diabetes-related 
kidney disease progression 








Muscle tissue Skeletal muscle Increases blood flow and 
metabolic rate 
Facilitates muscle activity, 
prevents ischemia  
Cardiac tissue Endothelial cells Increases NO production Cardioprotective effect, 
increases capillary blood 
flow 
Cardiomyocytes Increases blood flow metabolic 
rate and contractility 
Inotropic effect on left 
ventricular 
systolic function 
Vascular tissue Endothelial cells Decreased the expression of 




Smooth muscle cells Antiproliferative effects Can delay atherosclerosis. 







C-peptide was considered biologically inert. Latest data indicates that this assumption 
was wrong indicating multiple effects in the body. It can be proved useful to make additional 
injections of C-peptide or to create a drug with a combination of two peptides: insulin and C-
peptide. The use of C-peptide is still experimental in different other diseases but in case of T1D 
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